vs
Anika Therapeutics, Inc.（ANIK）とGLOBUS MEDICAL INC（GMED）の財務データ比較。上の社名をクリックして会社を切り替えられます
GLOBUS MEDICAL INCの直近四半期売上が大きい（$826.4M vs $30.6M、Anika Therapeutics, Inc.の約27.0倍）。GLOBUS MEDICAL INCの純利益率が高く（17.0% vs 1.0%、差は16.1%）。GLOBUS MEDICAL INCの前年同期比売上増加率が高い（25.7% vs 0.0%）。GLOBUS MEDICAL INCの直近四半期フリーキャッシュフローが多い（$202.4M vs $4.0M）。過去8四半期でGLOBUS MEDICAL INCの売上複合成長率が高い（16.7% vs 2.7%）
Globus Medical, Inc.は米国ペンシルベニア州オーダボンに本社を置く上場整形外科向け医療機器企業で、筋骨格系疾患の患者の治癒を促す製品の設計・開発・商用化に注力し、外科医による治療を支援している。
ANIK vs GMED — 直接比較
売上が大きい
GMED
27.0倍大きい
$30.6M
売上成長率が高い
GMED
+25.7%の差
0.0%
純利益率が高い
GMED
純利益率が16.1%高い
1.0%
フリーキャッシュフローが多い
GMED
FCF $198.4M多い
$4.0M
2年売上CAGRが高い
GMED
2年複合成長率
2.7%
損益計算書 — Q4 2025 vs Q4 2025
| 指標 | | |
|---|---|---|
| 売上 | $30.6M | $826.4M |
| 純利益 | $292.0K | $140.6M |
| 粗利率 | 62.6% | 68.4% |
| 営業利益率 | 2.1% | 20.5% |
| 純利益率 | 1.0% | 17.0% |
| 売上前年比 | 0.0% | 25.7% |
| 純利益前年比 | 101.3% | 430.4% |
| EPS（希薄化後） | $0.02 | $1.01 |
緑 = その指標でリード。会計年度がずれている場合は期間が異なる場合あり
8四半期 売上・利益トレンド
並べて比較する四半期履歴。決算期がずれていても暦四半期で整列
売上ANIKGMED
| Q4 25 | $30.6M | $826.4M | ||
| Q3 25 | $27.8M | $769.0M | ||
| Q2 25 | $28.2M | $745.3M | ||
| Q1 25 | $26.2M | $598.1M | ||
| Q4 24 | $30.6M | $657.3M | ||
| Q3 24 | $29.6M | $625.7M | ||
| Q2 24 | $30.7M | $629.7M | ||
| Q1 24 | $29.0M | $606.7M |
純利益ANIKGMED
| Q4 25 | $292.0K | $140.6M | ||
| Q3 25 | $-2.3M | $119.0M | ||
| Q2 25 | $-4.0M | $202.8M | ||
| Q1 25 | $-4.9M | $75.5M | ||
| Q4 24 | $-21.9M | $26.5M | ||
| Q3 24 | $-29.9M | $51.8M | ||
| Q2 24 | $-88.0K | $31.8M | ||
| Q1 24 | $-4.5M | $-7.1M |
粗利率ANIKGMED
| Q4 25 | 62.6% | 68.4% | ||
| Q3 25 | 56.0% | 67.2% | ||
| Q2 25 | 50.9% | 66.6% | ||
| Q1 25 | 56.1% | 67.3% | ||
| Q4 24 | 56.0% | 59.9% | ||
| Q3 24 | 65.7% | 56.8% | ||
| Q2 24 | 66.7% | 58.7% | ||
| Q1 24 | 65.4% | 60.2% |
営業利益率ANIKGMED
| Q4 25 | 2.1% | 20.5% | ||
| Q3 25 | -11.6% | 17.9% | ||
| Q2 25 | -14.8% | 10.2% | ||
| Q1 25 | -16.4% | 16.2% | ||
| Q4 24 | -2.3% | 9.2% | ||
| Q3 24 | -0.3% | 7.7% | ||
| Q2 24 | -5.9% | 7.9% | ||
| Q1 24 | -8.6% | 1.3% |
純利益率ANIKGMED
| Q4 25 | 1.0% | 17.0% | ||
| Q3 25 | -8.4% | 15.5% | ||
| Q2 25 | -14.1% | 27.2% | ||
| Q1 25 | -18.6% | 12.6% | ||
| Q4 24 | -71.4% | 4.0% | ||
| Q3 24 | -101.2% | 8.3% | ||
| Q2 24 | -0.3% | 5.0% | ||
| Q1 24 | -15.6% | -1.2% |
EPS（希薄化後）ANIKGMED
| Q4 25 | $0.02 | $1.01 | ||
| Q3 25 | $-0.16 | $0.88 | ||
| Q2 25 | $-0.28 | $1.49 | ||
| Q1 25 | $-0.34 | $0.54 | ||
| Q4 24 | $-1.49 | $0.19 | ||
| Q3 24 | $-2.03 | $0.38 | ||
| Q2 24 | $0.00 | $0.23 | ||
| Q1 24 | $-0.31 | $-0.05 |
貸借対照表と財務力
直近四半期の流動性・レバレッジ・純資産のスナップショット
| 指標 | | |
|---|---|---|
| 現金・短期投資手元流動性 | $81.2M | $557.2M |
| 総負債低いほど良い | — | — |
| 株主資本純資産 | $143.5M | $4.6B |
| 総資産 | $190.3M | $5.3B |
| 負債/資本比率低いほどレバレッジが低い | — | — |
8四半期トレンド — 暦四半期で整列
現金・短期投資ANIKGMED
| Q4 25 | $81.2M | $557.2M | ||
| Q3 25 | $80.2M | $18.8M | ||
| Q2 25 | $77.1M | — | ||
| Q1 25 | $75.4M | — | ||
| Q4 24 | $79.2M | $890.1M | ||
| Q3 24 | $90.7M | $71.9M | ||
| Q2 24 | $96.6M | $82.5M | ||
| Q1 24 | $100.7M | $80.4M |
株主資本ANIKGMED
| Q4 25 | $143.5M | $4.6B | ||
| Q3 25 | $146.8M | $4.4B | ||
| Q2 25 | $147.7M | $4.3B | ||
| Q1 25 | $148.4M | $4.1B | ||
| Q4 24 | $154.0M | $4.2B | ||
| Q3 24 | $179.9M | $4.1B | ||
| Q2 24 | $210.3M | $4.0B | ||
| Q1 24 | $208.5M | $3.9B |
総資産ANIKGMED
| Q4 25 | $190.3M | $5.3B | ||
| Q3 25 | $189.4M | $5.1B | ||
| Q2 25 | $187.7M | $5.0B | ||
| Q1 25 | $190.6M | $4.7B | ||
| Q4 24 | $202.7M | $5.3B | ||
| Q3 24 | $231.4M | $5.1B | ||
| Q2 24 | $262.7M | $5.0B | ||
| Q1 24 | $263.7M | $4.9B |
キャッシュフローと資本効率
再投資後に実際に生み出すキャッシュ。純利益より操作が難しい
| 指標 | | |
|---|---|---|
| 営業キャッシュフロー直近四半期 | $4.6M | $248.6M |
| フリーキャッシュフロー営業CF - 設備投資 | $4.0M | $202.4M |
| FCFマージンFCF / 売上 | 13.0% | 24.5% |
| 設備投資強度設備投資 / 売上 | 2.1% | 5.6% |
| キャッシュ転換率営業CF / 純利益 | 15.88× | 1.77× |
| 直近12ヶ月FCF直近4四半期 | $4.4M | $588.8M |
8四半期トレンド — 暦四半期で整列
営業キャッシュフローANIKGMED
| Q4 25 | $4.6M | $248.6M | ||
| Q3 25 | $6.9M | $249.7M | ||
| Q2 25 | $-189.0K | $77.9M | ||
| Q1 25 | $-130.0K | $177.3M | ||
| Q4 24 | $1.6M | $210.3M | ||
| Q3 24 | $5.0M | $203.7M | ||
| Q2 24 | $-1.1M | $54.3M | ||
| Q1 24 | $-126.0K | $52.4M |
フリーキャッシュフローANIKGMED
| Q4 25 | $4.0M | $202.4M | ||
| Q3 25 | $5.0M | $213.9M | ||
| Q2 25 | $-1.7M | $31.3M | ||
| Q1 25 | $-3.0M | $141.2M | ||
| Q4 24 | $275.0K | $193.2M | ||
| Q3 24 | $3.8M | $161.7M | ||
| Q2 24 | $-4.5M | $26.5M | ||
| Q1 24 | $-1.9M | $23.8M |
FCFマージンANIKGMED
| Q4 25 | 13.0% | 24.5% | ||
| Q3 25 | 17.9% | 27.8% | ||
| Q2 25 | -5.9% | 4.2% | ||
| Q1 25 | -11.3% | 23.6% | ||
| Q4 24 | 0.9% | 29.4% | ||
| Q3 24 | 12.9% | 25.8% | ||
| Q2 24 | -14.6% | 4.2% | ||
| Q1 24 | -6.7% | 3.9% |
設備投資強度ANIKGMED
| Q4 25 | 2.1% | 5.6% | ||
| Q3 25 | 6.8% | 4.7% | ||
| Q2 25 | 5.2% | 6.2% | ||
| Q1 25 | 10.8% | 6.0% | ||
| Q4 24 | 4.3% | 2.6% | ||
| Q3 24 | 4.1% | 6.7% | ||
| Q2 24 | 11.1% | 4.4% | ||
| Q1 24 | 6.2% | 4.7% |
キャッシュ転換率ANIKGMED
| Q4 25 | 15.88× | 1.77× | ||
| Q3 25 | — | 2.10× | ||
| Q2 25 | — | 0.38× | ||
| Q1 25 | — | 2.35× | ||
| Q4 24 | — | 7.94× | ||
| Q3 24 | — | 3.93× | ||
| Q2 24 | — | 1.71× | ||
| Q1 24 | — | — |
財務フロー比較
売上 → 粗利 → 営業利益 → 純利益のサンキー図
セグメント別売上内訳
ANIK
| OEM Channel | $17.3M | 57% |
| Commercial Channel | $13.3M | 43% |
GMED
| Other | $391.8M | 47% |
| Nevro Merger Agreement | $293.6M | 36% |
| Enabling Technologies | $141.0M | 17% |
